Mode
Text Size
Log in / Sign up
N/A N=1,150 Randomized Treatment

Randomized Endo-Vein Graft Prospective

Coronary Artery Bypass Grafting

Enrolled (actual)
1,150
Serious AEs
63.0%
Results posted
Nov 2021
Primary outcome: Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Vein Harvesting Procedures (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Sep 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of First MACE During Active Follow-up Period.
80; 89 0.47
SECONDARY
MACE at One Year.
45; 47 0.821
SECONDARY
MACE at Three Years.
90; 90 >0.99
SECONDARY
Incidence of First MACE Over the Entire Follow-up Period (Active and Passive).
126; 135 0.517

Summary

Coronary artery bypass grafting (CABG) is the most common major surgical procedure in the United States with over 300,000 cases performed each year. To restore blood flow to the heart, vascular conduits from another part of the body are procured to create a bypass around critically blocked coronary arteries. The left internal thoracic artery is the conduit of choice for CABG due to its superior long-term patency. However, almost all patients referred for CABG require additional grafts to provide complete revascularization. This necessitates the harvest of other vessels, most commonly the saphenous vein which is used almost ubiquitously in contemporary CABG with an average of two vein grafts per CABG procedure. In the last 10 years, Endoscopic Vein Harvesting (EVH) has been recommended as the preferred method over the traditional open harvesting technique (OVH) because it provides a minimally invasive approach. However, more recent investigations indicate potential for reduced long-term bypass graft patency and worse clinical outcomes with EVH. The long term impact of EVH on clinical outcomes has never been investigated on a large scale using a definitive, adequately powered, prospective Randomized Controlled Trial (RCT) with long-term follow-up.

Eligibility Criteria

Inclusion Criteria

  • Age years 18 years or older
  • Elective or Urgent CABG-only
  • Median sternotomy approach
  • At least one coronary bypass planned using saphenous vein graft for conduit
  • Experienced EVH/OVH harvester available for procedure

Exclusion Criteria

  • Combined valve procedure planned
  • Moderate or severe valve disease (see definition of moderate/severe valve)
  • Hemodynamically unstable or in cardiogenic shock
  • Enrolled in another therapeutic or interventional study
  • Off-pump CABG procedure planned
  • Limited life expectancy < 1 year
  • History of lower extremities venous stripping or ligation
  • Inability to provide informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01850082). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search